Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Distamab Vedotin Combined With Carboplatin for First-Line Advanced Ovarian Cancer
NCT07285941Phase 2Recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Jan 2025
- Primary completion
- Jan 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of disitamab vedotin in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Progression-Free Survival at 1 year. Started Jan 2025; status: recruiting.
02
Drugs
disitamab vedotin
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT07285941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07285941.